However , phase III results disclosed in January 2011 were disappointing .
In 2009 , the FDA began fast - tracking the new drug application of iniparib for triple - negative breast cancer .
Phase III results disclosed in January 2011 were disappointing .
In 2009 , the FDA began fast - tracking the new drug application of iniparib for triple - negative breast cancer .